CAS NO: | 1346547-00-9 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | GSK583 is a highly potent, orally active and selective inhibitor ofRIP2 Kinase, withIC50of 5 nM. GSK583 inhibits both TNF-α andIL-6production with an IC50value of 200 nM. | ||||||||||||||||
IC50& Target | IC50: 5 nM (RIP2K)[1] | ||||||||||||||||
体外研究 (In Vitro) | GSK583 (1 μM) exhibits excellent selectivity in a panel of 300 kinases, including p38α and VEGFR2. GSK583 potently and dose dependently inhibits MDP-stimulated tumor necrosis factor-alpha (TNFα) production with an IC50of 8 nM. GSK583 demonstrates only a modest reduction in potency when profiled in a similar MDP-induced TNFα production assay in human whole blood (IC50= 237 nM) and rat whole blood (IC50= 133 nM)[1]. | ||||||||||||||||
体内研究 (In Vivo) | GSK583 (0.1, 1, and 10 mg/kg, p.o.) inhibits serum KC (the rodent orthologue of IL-8) levels in rats in a dose-dependent manner, with an IC50derived from rat blood concentrations of 50 nM (or 20 ng/mL). Similarly, GSK583 inhibits serum KC levels and recruitment of neutrophils into the peritoneal cavity in mice in a dose-dependent manner, with an IC50of 37 nM (15 ng/mL) derived from mouse blood concentration[1]. | ||||||||||||||||
分子量 | 398.45 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C20H19FN4O2S | ||||||||||||||||
CAS 号 | 1346547-00-9 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(250.97 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|